Chronic myeloid leukemia following treatment for bilateral retinoblastoma

Kamitori, Tatsuya; Umeda, Katsutsugu; Tasaka, Kachio; Ogata, Hiroaki; Mikami, Takashi; Kato, Ikunoshin; Hiramatsu, Hidefumi; Kondo, Tadakazu; Adachi, Souichi

doi:10.1002/pbc.27107

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 1 ] CML is divided into chronic, accelerated, and blast phases, resulting from the t (9;22) (q34; q11) translocation. In addition to their case and another referenced by the authors,[ 2 ] there is a third case in the literature described by Gombos et al . [ 3 ] In that series, case #4 of acute myeloid leukemia (AML) appears actually to describe a case of CML in myeloid blast crisis 22 years after the diagnosis of RB.…”

mentioning

confidence: 78%

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma

Leahey

Shields

2021

Oman Journal of Ophthalmology

View full text Add to dashboard Cite

mentioning

confidence: 78%

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma

Leahey

Shields

2021

Oman Journal of Ophthalmology

View full text Add to dashboard Cite

“…There is only one reported case in the literature of CML in a patient with bilateral retinoblastoma. [ 10 ] The patient developed CML over 20 years following treatment and responded well to dasatinib. The authors speculate that the CML was related to external beam radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Chronic myelogenous leukemia in a child following treatment for bilateral retinoblastoma

Al-Mahrouqi

Ganesh

Al‐Rawas

et al. 2021

Oman Journal of Ophthalmology

View full text Add to dashboard Cite

A 3-year-old child was incidentally found to have chronic myelogenous leukemia (CML) during an admission for a routine ophthalmic examination under anesthesia. The child had received systemic chemotherapy and focal treatment for Groups C and D retinoblastoma in the right and left eye, respectively, when she was 7 months old. CML was treated with dasatinib, and the child attained a major molecular response. The child is now 3 years after treatment of CML, and the retinoblastoma remains inactive. CML following treatment of retinoblastoma is a rare occurrence. Long term and close monitoring of retinoblastoma patients who received systemic chemotherapy using serial blood tests is essential.

show abstract

Hematological Second Primary Malignancy in Pediatric Retinoblastoma: A Case Report and Systematic Review

Hyun Park,

Young Park,

Kim

et al. 2024

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: The impact of heredity and treatment modalities on the development of hematologic second primary malignancies (SPMs) is unclear. This study primarily reviewed the literature on patients with hematologic SPMs after retinoblastoma. Methods: The PubMed and Web of Science databases were searched to identify all cases of hematologic SPMs after retinoblastoma through December 2023 (International prospective register of systematic reviews CRD42023488273). Results: Sixty-one patients from 35 independent publications and our case were included. Within the cohort, 15 patients (51.7%) were male, and 14 patients (48.3%) were female. Of the 43 cases with known heritability status, 27 (62.8%) were classified as heritable and 16 (37.2%) as nonheritable. The median age at diagnosis was 18 months (IQR: 7.00–36.00). The geographic distribution of patients was diverse, with North America accounting for 35.0% (21/60) of cases. The following treatment strategies were used: 11.9% (5/42) of patients received neither chemotherapy nor radiotherapy, 33.3% (14/42) received chemotherapy alone, 11.9% (5/42) received radiotherapy alone, and 42.9% (18/42) received a combination of chemotherapy and radiotherapy. The median delay between retinoblastoma diagnosis and SPM diagnosis was 40 months (IQR: 22.00–85.00). Among the 61 cases, acute myeloid leukemia accounted for 44.3% (27/61), followed by acute lymphoblastic leukemia in 21.3% (13/61), Hodgkin’s lymphoma in 11.5% (7/61), non-Hodgkin’s lymphoma in 9.8% (6/61), chronic myeloid leukemia in 3.3% (2/61), and acute natural killer cell leukemia in 1.6% (1/61). Conclusions: Vigilant systemic surveillance for hematologic SPMs in retinoblastoma survivors, especially those treated with systemic chemotherapy and those with hereditary conditions, is warranted to improve management strategies and patient outcomes.

show abstract

Chronic myeloid leukemia following treatment for bilateral retinoblastoma

Cited by 3 publications

References 9 publications

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma

Chronic myeloid leukemia versus acute myeloid leukemia in patients with retinoblastoma

Chronic myelogenous leukemia in a child following treatment for bilateral retinoblastoma

Hematological Second Primary Malignancy in Pediatric Retinoblastoma: A Case Report and Systematic Review

Contact Info

Product

Resources

About